Data from the Phase 3 study POINT it Dengue vaccine Developed by institute Butantan 79% effective in preventing disease after two years of application. During the analysis, no cases of severe infection were recorded in the participants.
The information is still preliminary – the five-year vaccination follow-up still needs to be completed, which should only happen in 2024.
Only after that, will the institute Submit medication for Anvisa analysis (National Health Surveillance Agency), which is responsible for approval of vaccination or not.
The vaccine is a single dose and uses four attenuated viral strains. It’s called Butantan-DV, and it’s a similar version to the one developed by the US National Institute of Health. MSD Pharmaceuticals is also part of the Immunology Development Project.
Find who resides Vaccine efficacy data It began in 2016. In all, there were more than 16,000 volunteers between the ages of 2 and 59 in the survey, with about 10,000 volunteers receiving the placebo group.
Of all the participants, some had already been infected with the virus that causes dengue and It is transmitted by mosquitoes Aedes aegypti🇧🇷 Others are still unscathed.
Using this division, butantan was able to measure the overall efficacy of 79% of the vaccine, but also the differences observed in the two groups. For those with a history of dengue, the effectiveness was around 89%. For the other part of the participants without a history of the disease, the protection conferred by the vaccine was even lower – 73%.
Another peculiarity noted in the research was for virus serotypes🇧🇷 The vaccine is produced by four strains of the pathogen, called DENV-1, DENV-2, DENV-3, and DENV-4.
According to Butantan, serotypes 3 and 4 did not circulate widely in Brazil during the analysis period. Therefore, it was not possible to specifically infer vaccine efficacy for the two strains.
In the case of DENV-1 and DENV-2, the survey concluded that the vaccine had an overall efficacy of 89% for the first and 69% for the second.
In addition to the efficacy information, immune system safety was also measured. Butantan noted that in the group of immunized volunteers, less than 0.1% had reports of serious adverse events related to the vaccine.
The situation in Brazil
According to data from the Ministry of Health, dengue has already caused more than 1,400,100 probable cases in Brazil as of December 3 this year. The number is an increase 172% compared to last year’s information. Compared to 2019, the year before the pandemic, there was a 7.7% decrease in cases.
In total, there have been 1,414 serious case records this year, with 978 deaths.
“Writer. Analyst. Avid travel maven. Devoted twitter guru. Unapologetic pop culture expert. General zombie enthusiast.”
